Gastric Adenocarcinoma, Oesophageal Adenocarcinoma
Conditions
Brief summary
Oesophagogastric cancer (cancer of the gullet and stomach) is the fifth most common cancer in England and Wales with 16,000 new cases diagnosed every year. Survival rates are poor with only 15% surviving beyond 5 years. There is also increasing research to understand the cancer biology and factors allowing cancers to progress. It is likely there is a relationship between the cancer-specific microbiome, cells related to inflammation, which promotes cancer progression. The BIORESOURCE 1 study has established a comprehensive resource of matched samples from patients with oesophageal and gastric cancer. This longitudinal study aims to obtain further matched biosamples in the follow-up period after cancer surgery to find biomarkers that may predict treatment response, recurrence and/or long term prognosis.
Interventions
OTHERBiosample collection
Collection of saliva, urine, blood, breath and quality of life questionnaires.
Sponsors
Cancer Research UK
Imperial College London
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* Aged 18-90 years at the time of initial recruitment * Gastric/oesophageal adenocarcinoma cohort (biopsy proven adenocarcinoma) recruited into BIORESOURCE 1
Exclusion criteria
* Oesophageal squamous cell carcinoma * Previous oesophageal and gastric resection * History of another cancer within five years. If a new other cancer type is diagnosed within the sampling time frame, no further samples will be taken. * Participants with co-morbidities preventing breath collection * Unable or unwilling to provide informed written consent * Pregnant women
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Salivary microbial biomarkers to predict treatment response and long-term prognosis | 48 months | Changes in the presence and/or abundance of bacteria over a 2 year period, measured primarily within saliva. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Breath volatile organic compound profile alterations of oesophagogastric cancer pre- and post- treatment | 48 months | Changes in the VOC profile using gas chromatography mass spectrometry. |
| Quality of life measure up to 2 years following cancer surgery using validated questionnaires | 48 months | Assessment in the longitudinal changes of quality of life measures using validated questionnaires. |
Countries
United Kingdom
Contacts
Primary ContactBhamini Vadhwana, MRCS, PhD
Outcome results
None listed